GSK advances on plans to sell Lucozade and Ribena brands, Q1 results disappoint

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

FTSE 100-listed pharmaceuticals group GlaxoSmithKline (GSK) has announced plans to sell its Lucozade and Ribena brands during its less-than-impressive first quarter results, which showed a two per cent contraction in group sales.

Some analysts have suggested that the decision to sell the brands could earn the company in the region of £1.0bn.

GSK said that the results reflected the ongoing contribution from 'key growth drivers', which were offset by anticipated 'demanding' prior year comparisons.

Pre-tax profit for the period declined from £1.86bn to £1.41bn year-on-year.

Excluding the divestments primarily of Vesicare and non-core OTC brands, sales rose 2.0% during the period.

Pharmaceuticals and Vaccines sales fell 2.0%, while Consumer Healthcare rose 1.0%.

The group reported an adjusted net cash inflow from operating activities of £1.4bn, up from £1.1bn in the first quarter of 2012.

The group reported that during the period it had delivered core earnings per share of 26.9p and a dividend of 18p.

Sir Andrew Witty, Chief Executive Officer of GlaxoSmithKline, said: "This quarter marks continued strategic delivery for GSK with sales and earnings in line with our expectations, significant pipeline progress and further growth in our returns to shareholders through a 6.0% increase in the dividend."

He said that the group is implementing a "major new change programme" designed to improve the competitiveness of its European Pharmaceuticals business and also restructure its manufacturing and research and development businesses to simplify its operating model and release resources.

"The initial phases of these programmes are progressing well and remain on track to deliver total annual savings of at least £1.0bn by 2016. In the short term, the benefits of our restructuring programmes are not only helping to offset some of the margin pressure we are seeing due to the changing shape of our business but also are supporting the investment behind our continuing preparations for the launch of the pipeline," he said.

GlaxoSmithKline's share price was up 0.57% to 1,688p at 12:58 on Wednesday.

MF

Recommended

Share tips of the week – 28 January
Share tips

Share tips of the week – 28 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
28 Jan 2022
Which assets will benefit as the “jam tomorrow” bubble pops?
Investment strategy

Which assets will benefit as the “jam tomorrow” bubble pops?

With tech stocks, cryptocurrencies and many other “long duration” investments crashing hard, the “jam tomorrow” bubble looks to be bursting. John Step…
24 Jan 2022
Three innovative Asian stocks to buy now
Share tips

Three innovative Asian stocks to buy now

Professional investor Fay Ren of the Cerno Pacific Fund highlights three of her favourite Asian stocks to buy now
24 Jan 2022
Share tips of the week – 21 January
Share tips

Share tips of the week – 21 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
21 Jan 2022

Most Popular

Shareholder capitalism: why we must return power to listed companies’ ultimate owners
Investment strategy

Shareholder capitalism: why we must return power to listed companies’ ultimate owners

Under our system of shareholder capitalism it's not fund managers, it‘s the individual investors – the company's ultimate owners – who should be telli…
24 Jan 2022
Amazon halts plans to ban UK Visa credit card payments
Personal finance

Amazon halts plans to ban UK Visa credit card payments

Amazon has said that it is to shelve its proposed ban on UK customers making payments with Visa credit cards.
17 Jan 2022
Temple Bar’s Ian Lance and Nick Purves: the essence of value investing
Investment strategy

Temple Bar’s Ian Lance and Nick Purves: the essence of value investing

Ian Lance and Nick Purves of the Temple Bar investment trust explain the essence of “value investing” – buying something for less than its intrinsic v…
14 Jan 2022